King's College London

Research portal

Best Practices and Innovations for Managing Codeine Misuse and Dependence

Research output: Contribution to journalArticle

Standard

Best Practices and Innovations for Managing Codeine Misuse and Dependence. / Norman, Ian J; Bergin, Michael; Parry, Charles D; Van Hout, Marie Claire.

In: JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, Vol. 19, No. 3, 27.10.2016, p. 367-381.

Research output: Contribution to journalArticle

Harvard

Norman, IJ, Bergin, M, Parry, CD & Van Hout, MC 2016, 'Best Practices and Innovations for Managing Codeine Misuse and Dependence' JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES, vol. 19, no. 3, pp. 367-381. DOI: 10.18433/J3T89K

APA

Norman, I. J., Bergin, M., Parry, C. D., & Van Hout, M. C. (2016). Best Practices and Innovations for Managing Codeine Misuse and Dependence. DOI: 10.18433/J3T89K

Vancouver

Norman IJ, Bergin M, Parry CD, Van Hout MC. Best Practices and Innovations for Managing Codeine Misuse and Dependence. JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES. 2016 Oct 27;19(3):367-381. Available from, DOI: 10.18433/J3T89K

Author

Norman, Ian J ; Bergin, Michael ; Parry, Charles D ; Van Hout, Marie Claire. / Best Practices and Innovations for Managing Codeine Misuse and Dependence. In: JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES. 2016 ; Vol. 19, No. 3. pp. 367-381

Bibtex Download

@article{fcc306e4c1bf4fd5a5d44ce095970610,
title = "Best Practices and Innovations for Managing Codeine Misuse and Dependence",
abstract = "PURPOSE: Promoting and ensuring safe use of codeine containing medicines remains a public health issue given the rise in reporting of misuse and dependence particularly in countries where available over-the-counter (OTC). The aim of this unique study was to identify best practices in management of opioid abuse and dependence, particularly codeine, and innovations to meet challenges surrounding safe and compliant use, patient awareness-raising, reducing health harms and enhancing successful treatment of dependence.METHODS: A mixed methods approach using three data points was used that included : (1) analysis of data from existing scoping reviews to identify potential areas for innovation (2) interviews with key national stakeholders from public health, pharmaceutical, regulatory, primary care and addiction practice in three distinct regulatory regimes (Ireland, United Kingdom and South Africa); and (3) a circular email request for information on potential innovations to members of the European Medicine's Agency European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP). Data from these three sources were analysed to identify best practices and opportunities for innovation.RESULTS: Best practices and potential innovations were identified under the nine headings: (1) manufacture; (2) product information and public education; (3) responsible prescribing; (4) monitoring and surveillance; (5) dispensing, screening and brief interventions in community pharmacies; (6) safety in the workplace and on the road; (7) internet supply of codeine and online support; (8) treatment of codeine dependence; and (9) learning resources and training for health professionals.CONCLUSIONS: Challenges ensuring availability of codeine containing medicines for legitimate therapeutic use, while minimising misuse, dependence and related health harms warrant consideration of new innovations. Most promising innovative potential lies across the products' retail lifecycle from manufacture to prescriber and community pharmacy practitioner.This article is open to POST-PUBLICATION REVIEW. Registered readers (see {"}For Readers{"}) may comment by clicking on ABSTRACT on the issue's contents page.",
author = "Norman, {Ian J} and Michael Bergin and Parry, {Charles D} and {Van Hout}, {Marie Claire}",
year = "2016",
month = "10",
day = "27",
doi = "10.18433/J3T89K",
language = "English",
volume = "19",
pages = "367--381",
journal = "JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES",
issn = "1482-1826",
publisher = "Canadian Society for Pharmaceutical Sciences",
number = "3",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Best Practices and Innovations for Managing Codeine Misuse and Dependence

AU - Norman,Ian J

AU - Bergin,Michael

AU - Parry,Charles D

AU - Van Hout,Marie Claire

PY - 2016/10/27

Y1 - 2016/10/27

N2 - PURPOSE: Promoting and ensuring safe use of codeine containing medicines remains a public health issue given the rise in reporting of misuse and dependence particularly in countries where available over-the-counter (OTC). The aim of this unique study was to identify best practices in management of opioid abuse and dependence, particularly codeine, and innovations to meet challenges surrounding safe and compliant use, patient awareness-raising, reducing health harms and enhancing successful treatment of dependence.METHODS: A mixed methods approach using three data points was used that included : (1) analysis of data from existing scoping reviews to identify potential areas for innovation (2) interviews with key national stakeholders from public health, pharmaceutical, regulatory, primary care and addiction practice in three distinct regulatory regimes (Ireland, United Kingdom and South Africa); and (3) a circular email request for information on potential innovations to members of the European Medicine's Agency European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP). Data from these three sources were analysed to identify best practices and opportunities for innovation.RESULTS: Best practices and potential innovations were identified under the nine headings: (1) manufacture; (2) product information and public education; (3) responsible prescribing; (4) monitoring and surveillance; (5) dispensing, screening and brief interventions in community pharmacies; (6) safety in the workplace and on the road; (7) internet supply of codeine and online support; (8) treatment of codeine dependence; and (9) learning resources and training for health professionals.CONCLUSIONS: Challenges ensuring availability of codeine containing medicines for legitimate therapeutic use, while minimising misuse, dependence and related health harms warrant consideration of new innovations. Most promising innovative potential lies across the products' retail lifecycle from manufacture to prescriber and community pharmacy practitioner.This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.

AB - PURPOSE: Promoting and ensuring safe use of codeine containing medicines remains a public health issue given the rise in reporting of misuse and dependence particularly in countries where available over-the-counter (OTC). The aim of this unique study was to identify best practices in management of opioid abuse and dependence, particularly codeine, and innovations to meet challenges surrounding safe and compliant use, patient awareness-raising, reducing health harms and enhancing successful treatment of dependence.METHODS: A mixed methods approach using three data points was used that included : (1) analysis of data from existing scoping reviews to identify potential areas for innovation (2) interviews with key national stakeholders from public health, pharmaceutical, regulatory, primary care and addiction practice in three distinct regulatory regimes (Ireland, United Kingdom and South Africa); and (3) a circular email request for information on potential innovations to members of the European Medicine's Agency European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCEPP). Data from these three sources were analysed to identify best practices and opportunities for innovation.RESULTS: Best practices and potential innovations were identified under the nine headings: (1) manufacture; (2) product information and public education; (3) responsible prescribing; (4) monitoring and surveillance; (5) dispensing, screening and brief interventions in community pharmacies; (6) safety in the workplace and on the road; (7) internet supply of codeine and online support; (8) treatment of codeine dependence; and (9) learning resources and training for health professionals.CONCLUSIONS: Challenges ensuring availability of codeine containing medicines for legitimate therapeutic use, while minimising misuse, dependence and related health harms warrant consideration of new innovations. Most promising innovative potential lies across the products' retail lifecycle from manufacture to prescriber and community pharmacy practitioner.This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page.

U2 - 10.18433/J3T89K

DO - 10.18433/J3T89K

M3 - Article

VL - 19

SP - 367

EP - 381

JO - JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

T2 - JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

JF - JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES

SN - 1482-1826

IS - 3

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454